Gamida Cell Ltd. (GMDA) Prices 13.334M Share Common Offering at $4.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Gamida Cell Ltd. (GMDA) Tops Q1 EPS by 14c
May 21, 2020 8:02 AM EDTGamida Cell Ltd. (NASDAQ: GMDA) reported Q1 EPS of ($0.31), $0.14 better than the analyst estimate of ($0.45).
First Quarter 2020 Financial Results
Research and development expenses in the first quarter of 2020 were $7.9 million, compared to $7.3 million for the same period in 2019. The increase was mainly due to clinical activities relating to the advancement GDA-201, offset by grants received from the Israel Innovation Authority.Commercial expenses in the first quarter of 2020 were $1.5 million compared to $1.0 million for the same period in 2019. The increase was mainly attributed to commercial readiness activities for omidubicel.General and... MoreAfter-Hours Stock Movers 05/18: (ABUS) (DAC) (BIDU) Higher; (BLPH) (GMDA) (GOSS) Lower (more...)
May 18, 2020 5:44 PM EDTAfter-Hours Stock Movers:
Arbutus Biopharma Corporation (Nasdaq: ABUS) 55% HIGHER; reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) 14.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.
Gamida Cell... More
Gamida Cell Ltd. (GMDA) Announces Launch of Proposed Public Offering of Ordinary Shares
May 18, 2020 4:04 PM EDTGamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the launch of a proposed follow-on public offering of its ordinary shares. In addition, Gamida Cell expects to grant the underwriters a 30-day option to purchase up to an... More
